Prenetics Global (PRE) Projected to Post Quarterly Earnings on Thursday

Prenetics Global (NASDAQ:PRE) is expected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Prenetics Global to post earnings of ($0.66) per share and revenue of $37.9030 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 11:00 AM ET.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.22. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.61%. The company had revenue of $36.60 million during the quarter, compared to the consensus estimate of $36.15 million. On average, analysts expect Prenetics Global to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Prenetics Global Stock Performance

Shares of PRE opened at $15.90 on Thursday. Prenetics Global has a 1 year low of $5.07 and a 1 year high of $23.63. The company has a market cap of $267.57 million, a price-to-earnings ratio of -3.96 and a beta of 0.15. The firm has a fifty day moving average of $18.73 and a 200-day moving average of $17.01.

Prenetics Global declared that its Board of Directors has initiated a stock repurchase plan on Friday, March 6th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the company to buy up to 15.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Prenetics Global

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN acquired a new stake in Prenetics Global in the 4th quarter valued at about $47,000. JPMorgan Chase & Co. acquired a new stake in Prenetics Global in the 3rd quarter valued at about $65,000. Boothbay Fund Management LLC acquired a new stake in Prenetics Global in the 4th quarter valued at about $241,000. Jump Financial LLC acquired a new stake in Prenetics Global in the 4th quarter valued at about $268,000. Finally, Hudson Bay Capital Management LP acquired a new stake in Prenetics Global in the 4th quarter valued at about $296,000. 25.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Roth Mkm initiated coverage on shares of Prenetics Global in a report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Lake Street Capital initiated coverage on shares of Prenetics Global in a report on Monday, March 16th. They issued a “buy” rating and a $29.00 price objective for the company. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.33.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.